The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system characterized by demyelination and axonal loss. The etiology of MS is unknown; …

Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the
central nervous system. It affects approximately 400,000 people in the United States and …

The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …

Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing …

Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Multiple sclerosis (MS) is a central nervous system chronic inflammatory disease that is
characterized by an extensive and complex immune response. Scientific advances have …

With the introduction of interferon‐β1b in 1993 as the first FDA‐approved treatment for
multiple sclerosis, the era of treatment of this incurable disease began, and its natural …